{
    "clinical_study": {
        "@rank": "1660", 
        "arm_group": [
            {
                "arm_group_label": "tamoxifen", 
                "arm_group_type": "Active Comparator", 
                "description": "tamoxifen,20mg/day"
            }, 
            {
                "arm_group_label": "toremifene", 
                "arm_group_type": "Experimental", 
                "description": "toremifene,60mg/day"
            }
        ], 
        "brief_summary": {
            "textblock": "In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of\n      tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated\n      derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought\n      to compare the efficacy and tolerability of toremifene and tamoxifen therapy in\n      premenopausal patients with operable,estrogen and/or progesterone receptor positive breast\n      cancer patients."
        }, 
        "brief_title": "Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients", 
        "completion_date": {
            "#text": "May 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer Patients in Premenopausal", 
            "Estrogen and/or Progesterone Receptor Positive"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of Breast cancer\n\n          -  Received standard treatment (chemotherapy, operation, or radiotherapy)\n\n          -  premenopausal\n\n          -  estrogen and/or progesterone receptor positive\n\n        Exclusion Criteria:\n\n          -  Metastatic tumors\n\n          -  During pregnancy or lactation"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "3036", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132000", 
            "org_study_id": "BCSCO002"
        }, 
        "intervention": {
            "arm_group_label": [
                "tamoxifen", 
                "toremifene"
            ], 
            "intervention_name": "toremifene or tamoxifen", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Tamoxifen", 
                "Toremifene"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 3, 2014", 
        "location": {
            "contact": {
                "email": "yypapple1225@163.com", 
                "last_name": "Yaping yang, master", 
                "phone": "0086-020-34071145"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510000"
                }, 
                "name": "Breast cancer center of Sun Yat-sen Memorial Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Fengxi Su, Doctor", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Weijuan Jia, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ran Gu, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yaping Yang, Master", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "survival outcomes: disease free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "measure": "5-year overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132000"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University", 
            "investigator_full_name": "Fengxi Su", 
            "investigator_title": "Chief of Breast cancer center in Sun Yat-Sen Memorial Hospital", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "the primary safety measures are Hepatic function and blood lipid", 
                "measure": "side effects effects of therapies", 
                "safety_issue": "Yes", 
                "time_frame": "Follow-up period,up to 5 years"
            }, 
            {
                "description": "Adverse events including hot flashes,  irregular menses and others.", 
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "follow-up period, up to 5 years"
            }
        ], 
        "source": "Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fengxi Su", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}